Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics

Cell Death and Disease

Volumn 4, Issue 7, 2013, Pages

  Zheng, X ^a,b   Naiditch, J ^a   Czurylo, M ^a   Jie, C ^c   Lautz, T ^a   Clark, S ^a   Jafari, N ^c   Qiu, Y ^a   Chu, F ^a   Madonna, M B ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cancer stem cell; Drug resistance; Histone deacetylase inhibitor; Neuroblastoma

Indexed keywords

CALGRANULIN A; CD133 ANTIGEN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR SOX2; VORINOSTAT;

ABCC4 GENE; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; FLOW CYTOMETRY; GENE; GENE CONTROL; GENE EXPRESSION; GENOME ANALYSIS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LMO2 GENE; NEUROBLASTOMA CELL; ONCOGENE C MYB; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIM GENE;

CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; NEOPLASTIC STEM CELLS; NEUROBLASTOMA;

EID: 84881058837     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.264     Document Type: Article

References (59)

1. Olshan AF, Bunin GR. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (ed). Neuroblastoma. Elsevier Science: Amsterdam, 2000.
2. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-14233.
3. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR et al. Analysis of gene expression and chemoresistance of CD133\+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
4. Besancon R, Valsesia-Wittmann S, Puisieux A. Caron de Fromentel C, Maguer-Satta V. Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem 2009; 16: 394-416.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
6. Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007; 67: 11234-11243.
7. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320.
8. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
9. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
10. Wang J, Zhou JY, Wu GS. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res 2007; 67: 11933-11941.
11. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-251.
12. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010; 120: 3326-3339.
13. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
14. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 1997; 94: 5320-5325.
15. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
16. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L. Brca1 breast tumors contain distinct CD44\+/CD24-and CD133\+ cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10: R10.
17. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133\+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-824.
18. Lang SH, Frame FM, Collins AT. Prostate cancer stem cells. J Pathol 2009; 217: 299-306.
19. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514.
20. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
21. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al. Highly tumorigenic lung cancer CD133\+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009; 106: 16281-16286.
22. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010; 102: 1637-1652.
23. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009; 69: 1951-1957.
24. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett 2009; 280: 192-200.
25. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784.
26. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T et al. Epigenetic regulation of CD133 and tumorigenicity of CD133\+ ovarian cancer cells. Oncogene 2009; 28: 209-218.
27. Di Bernardo G, Alessio N, Dell'Aversana C, Casale F, Teti D, Cipollaro M et al. Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells. J Cell Physiol 2010; 225: 537-544.
28. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010; 17: 427-442.
29. Hermann PC, Huber SL, Heeschen C. Metastatic cancer stem cells: a new target for anticancer therapy? Cell Cycle 2008; 7: 188-193.
30. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J Pathol 2012; 229: 355-378.
31. Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L et al. CD133 expression in chemo-resistant Ewing sarcoma cells. BMC Cancer 2010; 10: 116.
32. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM et al. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 2009; 69: 1776-1781.
33. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G et al. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem 2010; 285: 4931-4940.
34. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009; 4: e4235.
35. Vangipuram SD, Wang ZJ, Lyman WD. Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents. Pediatr Blood Cancer 2010; 54: 361-368.
36. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 2002; 298: 597-600.
37. Geschwind DH, Ou J, Easterday MC, Dougherty JD, Jackson RL, Chen Z et al. A genetic analysis of neural progenitor differentiation. Neuron 2001; 29: 325-339.
38. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009; 14: 3-9.
39. Mohlin S, Pietras A, Wigerup C, Ora I, Andang M, Nilsson K et al. Tumor-initiating cells in childhood neuroblastoma-letter. Cancer Res 2012; 72: 821-822; author reply 823.
40. Steiniger SC, Coppinger JA, Kruger JA, Yates J 3rd, Janda KD. Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells 2008; 26: 3037-3046.
41. Newton TC, Wolcott K, Roberts SS. Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines. Transl Oncol 2010; 3: 246-251.
42. Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco MM et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res 2003; 5: R1-R8.
43. Lassalle B, Bastos H, Louis JP, Riou L, Testart J, Dutrillaux B et al. 'Side Population' cells in adult mouse testis express Bcrp1 gene and are enriched in spermatogonia and germinal stem cells. Development 2004; 131: 479-487.
44. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034.
45. Cournoyer S, Nyalendo C, Addioui A, Belounis A, Beaunoyer M, Aumont A et al. Genotype analysis of tumor-initiating cells expressing CD133 in neuroblastoma. Genes Chromosomes Cancer 2012; 51: 792-804.
46. Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, Duval M et al. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway. Histopathology 2012; 60: 1144-1155.
47. Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 2011; 30: 97-105.
48. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007; 99: 1107-1119.
49. Milde T, Kleber S, Korshunov A, Witt H, Hielscher T, Koch P et al. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. Acta Neuropathol 2011; 122: 637-650.
50. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C et al. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 2011; 103: 1236-1251.
51. Ring KL, Tong LM, Balestra ME, Javier R, Andrews-Zwilling Y, Li G et al. Direct reprogramming of mouse and human fibroblasts into multipotent neural stem cells with a single factor. Cell Stem Cell 2012; 11: 100-109.
52. Lluis F, Ombrato L, Pedone E, Pepe S, Merrill BJ, Cosma MP. T-cell factor 3 (Tcf3) deletion increases somatic cell reprogramming by inducing epigenome modifications. Proc Natl Acad Sci USA 2011; 108: 11912-11917.
53. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002; 298: 601-604.
54. Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 2008; 3: 132-135.
55. Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci USA 1998; 95: 3890-3895.
56. Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH. The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development. Cell 1994; 78: 45-57.
57. Dang H, Lin AL, Zhang B, Zhang HM, Katz MS, Yeh CK. Role for Notch signaling in salivary acinar cell growth and differentiation. Dev Dyn 2009; 238: 724-731.
58. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547-1548.
59. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.